Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis
Open Access
- 15 October 1991
- Vol. 68 (8) , 1795-1798
- https://doi.org/10.1002/1097-0142(19911015)68:8<1795::aid-cncr2820680824>3.0.co;2-i
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.Gut, 1987
- CA 19-9 and pancreatic adenocarcinomaCancer, 1986
- Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreasGastroenterology, 1986
- Prospective Evaluation of the Diagnostic Efficacy of CA 19–9 Assay as a Marker for Gastrointestinal CancersDigestion, 1986
- Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumorCancer, 1985
- Measurement of a monoclonal-antibody-defined antigen (CA 19-9) in the sera of patients with malignant and nonmalignant diseases comparison with carcinoembryonic antigenCancer, 1985
- Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.Gut, 1985
- CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitisEuropean Journal of Cancer and Clinical Oncology, 1985
- Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bankInternational Journal of Cancer, 1984
- Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.Journal of Clinical Pathology, 1984